Abstract
Despite the wide dissemination of information on Helicobacter pylori, there is still a great deal of variation in how general practitioners treat the infection and in which circumstances they prescribe eradication therapy for H. pylori. Specialty societies have developed consensus guidelines that recommend a strategy to test and treat dyspeptic patients for H. pylori infection although the data to support these recommendations are weak at the present time. As a result, there is still confusion about the indications for treatment and the treatment regimens that are likely to be effective in routine clinical practice.
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Ulcer Agents / economics
-
Anti-Ulcer Agents / therapeutic use
-
Bismuth / therapeutic use
-
Clarithromycin / therapeutic use
-
Cost-Benefit Analysis
-
Drug Therapy, Combination
-
Dyspepsia / drug therapy*
-
Dyspepsia / economics
-
Dyspepsia / microbiology
-
Enzyme Inhibitors / therapeutic use
-
Guidelines as Topic
-
Helicobacter Infections / drug therapy*
-
Helicobacter Infections / economics
-
Helicobacter pylori*
-
Humans
-
Lansoprazole
-
Omeprazole / analogs & derivatives
-
Omeprazole / therapeutic use
-
Peptic Ulcer / drug therapy*
-
Peptic Ulcer / economics
-
Peptic Ulcer / microbiology
-
Primary Health Care / methods
-
Ranitidine / analogs & derivatives
-
Ranitidine / therapeutic use
-
United States
-
United States Food and Drug Administration
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Anti-Bacterial Agents
-
Anti-Ulcer Agents
-
Enzyme Inhibitors
-
Lansoprazole
-
ranitidine bismuth citrate
-
Ranitidine
-
Clarithromycin
-
Omeprazole
-
Bismuth